- Home
- ARQT vs UWMC Comparison
ARQT vs UWMC Comparison
Compare ARQT & UWMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- UWMC
- Stock Information
- Founded
- ARQT 2016
- UWMC 1986
- Country
- ARQT United States
- UWMC United States
- Employees
- ARQT N/A
- UWMC N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- UWMC Finance: Consumer Services
- Sector
- ARQT Health Care
- UWMC Finance
- Exchange
- ARQT Nasdaq
- UWMC Nasdaq
- Market Cap
- ARQT 1.1B
- UWMC 971.2M
- IPO Year
- ARQT 2020
- UWMC N/A
- Fundamental
- Price
- ARQT $14.99
- UWMC $5.89
- Analyst Decision
- ARQT Strong Buy
- UWMC Hold
- Analyst Count
- ARQT 4
- UWMC 8
- Target Price
- ARQT $15.50
- UWMC $7.41
- AVG Volume (30 Days)
- ARQT 2.2M
- UWMC 3.1M
- Earning Date
- ARQT 11-06-2024
- UWMC 11-07-2024
- Dividend Yield
- ARQT N/A
- UWMC 6.80%
- EPS Growth
- ARQT N/A
- UWMC N/A
- EPS
- ARQT N/A
- UWMC N/A
- Revenue
- ARQT $138,708,000.00
- UWMC $2,727,467,000.00
- Revenue This Year
- ARQT $208.32
- UWMC $2.19
- Revenue Next Year
- ARQT $48.56
- UWMC $26.43
- P/E Ratio
- ARQT N/A
- UWMC N/A
- Revenue Growth
- ARQT 182.84
- UWMC 29.95
- 52 Week Low
- ARQT $2.60
- UWMC $5.44
- 52 Week High
- ARQT $15.77
- UWMC $9.74
- Technical
- Relative Strength Index (RSI)
- ARQT 67.53
- UWMC 40.82
- Support Level
- ARQT $12.66
- UWMC $5.44
- Resistance Level
- ARQT $15.02
- UWMC $6.48
- Average True Range (ATR)
- ARQT 1.11
- UWMC 0.27
- MACD
- ARQT 0.14
- UWMC -0.04
- Stochastic Oscillator
- ARQT 78.92
- UWMC 37.71
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale and servicing of residential mortgage loans. The company provides independent mortgage advisors across the states and the district of Columbia.